GlassScriptPhysician profile
Stephanie M Owens
NPI 1710170717
$1,931.96
in general payments reported to CMS, 2019-2025
22 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $44.92 · 2021: $38.92 · 2022: $162 · 2023: $669 · 2024: $216 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.91 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $536.97 | 2019-2025 | Acessa Provu System, Omni Hysteroscope, Coolseal Generator |
| Astellas Pharma US INC | $247.53 | 2023 | Veozah, Myrbetriq |
| Pfizer INC. | $211.23 | 2019-2023 | |
| Therapeuticsmd, INC. | $160.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.19 | 2022-2025 | |
| Abbvie INC. | $101.83 | 2019-2022 | |
| Exeltis, USA INC. | $78.39 | 2019-2025 | Slynd |
| Sage Therapeutics, LLC | $67.26 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $65.53 | 2023-2025 | Myfembree |
| Covidien LP | $59.43 | 2019-2020 | |
| Coopersurgical, INC. | $47.52 | 2019-2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $38.24 | 2023-2024 | Gardasil 9, Gardasil |
| Organon LLC | $23.09 | 2024 | |
| Scynexis, INC. | $22.86 | 2022 | |
| Si-Bone, INC. | $21.29 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $20.24 | 2022 | |
| Mayne Pharma Commercial LLC | $19.83 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $17.61 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $16.21 | 2019 | |
| Ethicon US, LLC | $16.15 | 2019 | |
| Medicem INC. | $15.50 | 2023 | |
| Vertical Pharmaceuticals, LLC | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.